Zobrazeno 1 - 10
of 69
pro vyhledávání: '"I N Dyakov"'
Autor:
I N Dyakov, M G Glezer
Publikováno v:
Терапевтический архив, Vol 88, Iss 11, Pp 83-90 (2016)
Aim. To pharmacoeconomically estimate the use of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients. Materials and methods. A pharmacoeconomic study was conducted on the basis of the Russian postmarketing
Externí odkaz:
https://doaj.org/article/ece277d305714f3196a5c2de93400b73
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 17, Iss 2, Pp 129-136 (2024)
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and
Externí odkaz:
https://doaj.org/article/338b38071e0947d4a72c818883742e92
Autor:
S. К. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 17, Iss 1, Pp 22-29 (2024)
Objective: to evaluate the pharmacoeconomic efficacy of “atezolizumab + bevacizumab + paclitaxel + carboplatin” drug combination compared to “pembrolizumab + pemetrexed + carboplatin” combination in adult patients with non-small cell lung can
Externí odkaz:
https://doaj.org/article/557de269226e485abb3da016a266dd6b
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 16, Iss 3, Pp 422-430 (2023)
Objective: to evaluate the pharmacoeconomic efficiency of atezolizumab (inhibitor of programmed death ligand 1 (PD-L1)) in comparison with other checkpoint inhibitors (inhibitors of programmed cell death protein 1 (PD-1)) in patients with advanced no
Externí odkaz:
https://doaj.org/article/5656c1d6fa50463293e6ecaf843b805f
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 70-84 (2023)
Objective. Comparative pharmacoeconomic evaluation of upadacitinib, baricitinib and dupilumab for the treatment of moderate to severe atopic dermatitis.Materials and methods. Study design — retrospective. Pharmacoeconomic analysis method — cost-e
Externí odkaz:
https://doaj.org/article/d904af2afb0842bd8bf9ad1aacfb463f
Autor:
I. N. Dyakov
Publikováno v:
Онкогематология, Vol 18, Iss 1, Pp 76-87 (2023)
Aim. To assess the pharmacoeconomic feasibility of using polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in 1st line therapy of adult patients with diffuse large B-cell lymphoma in the Russian
Externí odkaz:
https://doaj.org/article/014ebf8a7ef147fb97fb0acd057b957f
Autor:
G. I. Karataev, A. Yu. Medkova, E. G. Semin, L. N. Sinyashina, R. A. Sioundioukova, S. V. Kulikov, N. A. Snegireva, I. N. Chernishova, M. V. Gavrilova, K. K. Bushkova, A. A. Lidzhieva, L. V. Kolobukhina, I. S. Kruzhkova, L. N. Merkulova, M. G. Rusanova, M. V. Bazarova, N. A. Antipyat, S. V. Smetanina, E. A. Smolyarchuk, I. N. Dyakov
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 11, Iss 3, Pp 202-208 (2022)
Introduction. The increase in the incidence of whooping cough in children and adults of different age groups justifies the need for their revaccination and the development of new, acceptable for these purposes. This work is devoted to substantiating
Externí odkaz:
https://doaj.org/article/c0d1a9548af14ba7b9ab19978c99830b
Autor:
I. N. Dyakov, K. K. Bushkova
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 160-170 (2022)
Aim. To evaluate the pharmacoeconomic feasibility of using polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.Materi
Externí odkaz:
https://doaj.org/article/f863393bf0e448c5a52a37111fa1126d
Autor:
S. К. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 15, Iss 2, Pp 188-198 (2022)
Objective: to evaluate the pharmacoeconomic effectiveness of the use of a fixed double combination of tiotropium bromide + olodаterol in order to treat chronic obstructive pulmonary disease (COPD) in comparison with less expensive monotherapy with l
Externí odkaz:
https://doaj.org/article/3fc53697e83c48f6b96c40abc507c6a1
Autor:
A. A. Djidaryan, A. Z. Matua, A. Yu. Medkova, E. G. Semin, L. N. Sinyashina, I. N. Dyakov, I. N. Chernyshova, D. T. Kubrava, A. A. Amichba, I. G. Kondzariya, Z. Ya. Mikvabiya, G. I. Karataev
Publikováno v:
Журнал микробиологии, эпидемиологии и иммунобиологии, Vol 99, Iss 2, Pp 203-214 (2022)
Introduction. The Gamaleya National Center of Epidemiology and Microbiology has developed a live intranasal pertussis vaccine, GamLVP, for protection against whooping cough. It is indicated for vaccination of infants and revaccination of adults of al
Externí odkaz:
https://doaj.org/article/d090f35323d34678864b5e82237fdb39